About
Candel Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
Yesterday
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Apr 29 2026
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
Mar 17 2026
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
Mar 12 2026
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Mar 9 2026
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
Recent Videos

CADL Stock Analysis | Candel Therapeutics Inc Stock Latest Update & Chart Review
May 05, 2026

POTENTIAL UPSIDE | CADL STOCK ANALYSIS | CANDEL THERAPEUTICS STOCK
Apr 25, 2026

CADL STOCK : NEXT BIG SWING | CANDEL THERAPEUTICS STOCK
Apr 19, 2026

Cómo invertir en Candel Therapeutics Inc (CADL)
Mar 23, 2026
Translate